Summary

Persistence Market Research, a leading market research firm, has conducted an in-depth analysis of the global Acquired Orphan Blood Disease Market. This comprehensive report provides valuable insights into key market dynamics, growth drivers, challenges, and emerging trends. It offers a detailed overview of the segment within the rare disease therapeutics market, presenting exclusive data and statistics projecting the market's growth trajectory from 2024 to 2032.

Key Insights:

• Acquired Orphan Blood Disease Market Size (2024): US$ 9.6 Bn
• Projected Market Value (2032): US$ 21.5 Bn
• Global Market Growth Rate (CAGR 2024 to 2032): 10.6%

Acquired Orphan Blood Disease Market - Report Scope:

The Acquired Orphan Blood Disease Market encompasses a range of rare hematologic disorders characterized by acquired abnormalities in blood cell production, function, or regulation, leading to serious health consequences and life-threatening complications. These diseases include acquired hemophilia, acquired aplastic anemia, acquired thrombotic thrombocytopenic purpura (TTP), and paroxysmal nocturnal hemoglobinuria (PNH), among others. While individually rare, these conditions collectively affect a significant number of patients worldwide, presenting complex diagnostic and therapeutic challenges. The market serves pharmaceutical companies, biotechnology firms, academic research institutions, and healthcare providers, offering novel therapies, supportive care measures, and diagnostic tools for the management of acquired orphan blood diseases. Market growth is driven by increasing disease awareness, advancements in precision medicine, and growing investment in orphan drug development targeting rare hematologic disorders.

Market Growth Drivers:

The global Acquired Orphan Blood Disease Market benefits from several key growth drivers. Advances in molecular diagnostics, genetic testing, and biomarker discovery have improved disease detection, differential diagnosis, and risk stratification in patients with acquired blood disorders, enabling personalized treatment approaches and targeted interventions. Moreover, growing understanding of the underlying pathophysiology and molecular mechanisms of acquired orphan blood diseases has led to the identification of novel therapeutic targets and the development of innovative biologic agents, small molecules, and gene therapies for disease management. Additionally, regulatory incentives, orphan drug designations, and market exclusivity provisions have incentivized pharmaceutical companies to invest in rare disease research and drug development, driving innovation and market expansion in the field. Furthermore, patient advocacy efforts, clinical trial networks, and collaborative research consortia play a critical role in raising disease awareness, promoting early diagnosis, and accelerating patient access to innovative therapies in the competitive landscape of rare hematologic disorders.

Market Restraints:

Despite its promising growth prospects, the Acquired Orphan Blood Disease Market faces challenges related to disease heterogeneity, clinical trial design, and market access barriers. The rarity and clinical variability of acquired blood disorders pose challenges for clinical trial recruitment, patient stratification, and data interpretation, leading to small patient cohorts, limited statistical power, and challenges in demonstrating treatment efficacy and safety. Moreover, the high cost of orphan drug development, regulatory requirements, and reimbursement challenges may deter pharmaceutical companies from investing in rare disease research and drug commercialization, particularly for conditions with limited patient populations and unmet medical needs. Additionally, the complexity of disease management, including the need for multidisciplinary care, supportive therapies, and long-term monitoring, may strain healthcare resources and limit patient access to specialized care and innovative treatments. Addressing these barriers requires collaborative efforts between industry stakeholders, regulatory agencies, patient advocacy groups, and healthcare providers to streamline drug development pathways, expedite regulatory review processes, and improve patient access to orphan drugs and supportive care services.

Market Opportunities:

The Acquired Orphan Blood Disease Market presents significant growth opportunities driven by technological innovations, research advancements, and patient-centered care models. Emerging trends such as precision medicine, targeted therapy, and gene editing offer new avenues for disease understanding, treatment optimization, and patient outcomes in acquired orphan blood disorders. The development of gene-based therapies, including gene replacement, gene editing, and gene silencing approaches, holds promise for the treatment of genetic mutations underlying acquired hematologic disorders, such as acquired hemophilia and PNH. Moreover, advancements in cell therapy, immunotherapy, and regenerative medicine offer potential curative options for patients with refractory or relapsed disease, transforming the treatment landscape and improving long-term outcomes in the competitive field of rare hematologic disorders. Furthermore, strategic partnerships, collaborative research initiatives, and patient engagement programs are essential to accelerate drug development, foster innovation, and enhance patient access to breakthrough therapies in the evolving landscape of acquired orphan blood diseases.

Competitive Intelligence and Business Strategy:

Leading players in the global Acquired Orphan Blood Disease Market, including pharmaceutical companies, biotechnology firms, and academic research institutions, focus on innovation, collaboration, and patient-centric approaches to drive market growth and improve clinical outcomes. These companies invest in research and development to identify novel therapeutic targets, develop innovative drug candidates, and advance precision medicine approaches tailored to individual patient needs and disease subtypes within the acquired orphan blood disorder spectrum. Moreover, strategic collaborations with key opinion leaders, patient advocacy groups, and regulatory agencies enable companies to leverage clinical expertise, patient insights, and regulatory guidance to optimize drug development strategies, expedite clinical trial recruitment, and navigate regulatory pathways for orphan drug approval. Additionally, emphasis on patient-centered care models, multidisciplinary collaboration, and real-world evidence generation enhances treatment outcomes, patient adherence, and quality of life in the competitive landscape of rare hematologic disorders.

Key Companies Profiled:

• Alexion Pharmaceuticals, Inc.
• Amgen, Inc.
• Celgene Corporation
• Eli Lilly and Company
• Sanofi S.A.
• GlaxoSmithKline plc.
• Cyclacel Pharmaceuticals, Inc.
• Onconova Therapeutics, Inc.
• Incyte Corporation
• CTI BioPharma Corp.

Acquired Orphan Blood Disease Market Research Segmentation:

By Therapy:

• Recombinant Factor
• Immunoglobulin Infusion Therapy
• Activated Prothrombin Complex Concentrate
• Thrombopoietin Receptor Agonists
• Others

By Disease Indication:

• Acquired Agranulocytosis
• Acquired Hemophilia
• Acquired Von Willebrand Syndrome
• Paroxysmal Nocturnal Hemoglobinuria (PNH)
• Myelodysplastic Syndrome
• Other

By Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Others

By Region:

• North America
• Europe
• Latin America
• East Asia
• The Middle East & Africa
• South Asia & Pacific

ページTOPに戻る

Table of Contents

1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Technology Roadmap
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
4. Key Success Factors
4.1. Product Adoption / Usage Analysis
4.2. Product USPs / Features
4.3. Strategic Promotional Strategies
5. Global Acquired Orphan Blood Disease Market Demand Analysis 2019-2023 and Forecast, 2024-2032
5.1. Historical Market Volume (Tons) Analysis, 2019-2023
5.2. Current and Future Market Volume (Tons) Projections, 2024-2032
5.3. Y-o-Y Growth Trend Analysis
6. Global Acquired Orphan Blood Disease Market - Pricing Analysis
6.1. Regional Pricing Analysis By Therapy
6.2. Global Average Pricing Analysis Benchmark
7. Global Acquired Orphan Blood Disease Market Demand (in Value or Size in US$ Bn) Analysis 2019-2023 and Forecast, 2024-2032
7.1. Historical Market Value (US$ Bn) Analysis, 2019-2023
7.2. Current and Future Market Value (US$ Bn) Projections, 2024-2032
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Market Background
8.1. Macro-Economic Factors
8.1.1. Global GDP Growth Outlook
8.1.2. Global Industry Value Added Overview
8.1.3. Global Infrastructure Investment Overview
8.1.4. Global Construction Spending Analysis
8.1.5. Other Macro Economic Factors
8.2. Forecast Factors - Relevance & Impact
8.2.1. Top Companies Historical Growth
8.2.2. GDP Growth forecast
8.2.3. Construction Industry forecast
8.2.4. Distribution Channel Growth Outlook
8.2.5. Collaboration Activities
8.3. Value Chain
8.3.1. Raw Material Suppliers
8.3.2. List of Manufacturers
8.3.3. List of Distributors
8.4. COVID-19 Crisis – Impact Assessment
8.4.1. Current Statistics
8.4.2. Short-Mid-Long Term Outlook
8.4.3. Likely Rebound
8.5. Market Dynamics
8.5.1. Drivers
8.5.2. Restraints
8.5.3. Opportunity Analysis
8.5.4. Trends
9. Global Acquired Orphan Blood Disease Market Analysis 2019-2023 and Forecast 2024-2032, by Therapy
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Bn) and Volume Analysis by Type, 2019-2023
9.3. Current and Future Market Size (US$ Bn) and Volume Analysis and Forecast by Therapy 2024-2032
9.3.1. Recombinant Factor
9.3.2. Immunoglobulin Infusion Therapy
9.3.3. Activated Prothrombin Complex Concentrate
9.3.4. Thrombopoietin Receptor Agonists
9.3.5. Others
9.4. Market Attractiveness Analysis by Therapy
10. Global Acquired Orphan Blood Disease Market Analysis 2019-2023 and Forecast 2024-2032, By Disease Indication
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Bn) and Volume Analysis By Disease Indication, 2019-2023
10.3. Current and Future Market Size (US$ Bn) and Volume Analysis and Forecast By Disease Indication, 2024-2032
10.3.1. Acquired Agranulocytosis
10.3.2. Acquired Hemophilia
10.3.3. Acquired Von Willebrand Syndrome
10.3.4. Paroxysmal Nocturnal Hemoglobinuria (PNH)
10.3.5. Myelodysplastic Syndrome
10.3.6. Others
10.4. Market Attractiveness Analysis By Disease Indication
11. Global Acquired Orphan Blood Disease Market Analysis 2019-2023 and Forecast 2024-2032, By Distribution Channel
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Bn) and Volume Analysis By Distribution Channel, 2019-2023
11.3. Current and Future Market Size (US$ Bn) and Volume Analysis and Forecast By Distribution Channel 2024-2032
11.3.1. Hospital Pharmacy
11.3.2. Retail Pharmacy
11.3.3. Others
11.4. Market Attractiveness Analysis By Distribution Channel
12. Global Acquired Orphan Blood Disease Market Analysis 2019-2023 and Forecast 2024-2032, by Region
12.1. Introduction
12.2. Historical Market Size (US$ Bn) and Volume Analysis by Region, 2019-2023
12.3. Current Market Size (US$ Bn) and Volume Analysis and Forecast by Region, 2024-2032
12.3.1. North America
12.3.2. Latin America
12.3.3. Europe
12.3.4. East Asia
12.3.5. South Asia and Pacific
12.3.6. Middle East and Africa (MEA)
12.4. Market Attractiveness Analysis By Region
13. North America Acquired Orphan Blood Disease Market Analysis 2019-2023 and Forecast 2024-2032
13.1. Introduction
13.2. Pricing Analysis
13.3. Historical Market Size (US$ Bn) and Volume Trend Analysis by Market Taxonomy, 2019-2023
13.4. Market Size (US$ Bn) and Volume Forecast by Market Taxonomy, 2024-2032
13.4.1. By Country
13.4.1.1. U.S.
13.4.1.2. Canada
13.4.2. By Type
13.4.3. By Disease Indication
13.4.4. By Distribution Channel
13.5. Market Attractiveness Analysis
13.5.1. By Country
13.5.2. By Type
13.5.3. By Disease Indication
13.5.4. By Distribution Channel
13.6. Market Trends
13.7. Key Market Participants - Intensity Mapping
13.8. Drivers and Restraints - Impact Analysis
14. Latin America Acquired Orphan Blood Disease Market Analysis 2019-2023 and Forecast 2024-2032
14.1. Introduction
14.2. Pricing Analysis
14.3. Historical Market Size (US$ Bn) and Volume Trend Analysis by Market Taxonomy, 2019-2023
14.4. Market Size (US$ Bn) and Volume Forecast by Market Taxonomy, 2024-2032
14.4.1. By Country
14.4.1.1. Brazil
14.4.1.2. Mexico
14.4.1.3. Rest of Latin America
14.4.2. By Type
14.4.3. By Disease Indication
14.4.4. By Distribution Channel
14.5. Market Attractiveness Analysis
14.5.1. By Country
14.5.2. By Type
14.5.3. By Disease Indication
14.5.4. By Distribution Channel
14.6. Market Trends
14.7. Key Market Participants - Intensity Mapping
14.8. Drivers and Restraints - Impact Analysis
15. Europe Acquired Orphan Blood Disease Market Analysis 2019-2023 and Forecast 2024-2032
15.1. Introduction
15.2. Pricing Analysis
15.3. Historical Market Size (US$ Bn) and Volume Trend Analysis by Market Taxonomy, 2019-2023
15.4. Market Size (US$ Bn) and Volume Forecast by Market Taxonomy, 2024-2032
15.4.1. By Country
15.4.1.1. Germany
15.4.1.2. Italy
15.4.1.3. France
15.4.1.4. U.K.
15.4.1.5. Spain
15.4.1.6. BENELUX
15.4.1.7. Russia
15.4.1.8. Rest of Europe
15.4.2. By Type
15.4.3. By Disease Indication
15.4.4. By Distribution Channel
15.5. Market Attractiveness Analysis
15.5.1. By Country
15.5.2. By Type
15.5.3. By Disease Indication
15.5.4. By Distribution Channel
15.6. Market Trends
15.7. Key Market Participants - Intensity Mapping
15.8. Drivers and Restraints - Impact Analysis
16. South Asia and Pacific Acquired Orphan Blood Disease Market Analysis 2019-2023 and Forecast 2024-2032
16.1. Introduction
16.2. Pricing Analysis
16.3. Historical Market Size (US$ Bn) and Volume Trend Analysis by Market Taxonomy, 2019-2023
16.4. Market Size (US$ Bn) and Volume Forecast by Market Taxonomy, 2024-2032
16.4.1. By Country
16.4.1.1. India
16.4.1.2. ASEAN
16.4.1.3. Oceania
16.4.1.4. Rest of South Asia & Pacific
16.4.2. By Type
16.4.3. By Disease Indication
16.4.4. By Distribution Channel
16.5. Market Attractiveness Analysis
16.5.1. By Country
16.5.2. By Type
16.5.3. By Disease Indication
16.5.4. By Distribution Channel
16.6. Market Trends
16.7. Key Market Participants - Intensity Mapping
16.8. Drivers and Restraints - Impact Analysis
17. East Asia Acquired Orphan Blood Disease Market Analysis 2019-2023 and Forecast 2024-2032
17.1. Introduction
17.2. Pricing Analysis
17.3. Historical Market Size (US$ Bn) and Volume Trend Analysis by Market Taxonomy, 2019-2023
17.4. Market Size (US$ Bn) and Volume Forecast by Market Taxonomy, 2024-2032
17.4.1. By Country
17.4.1.1. China
17.4.1.2. Japan
17.4.1.3. South Korea
17.4.2. By Type
17.4.3. By Disease Indication
17.4.4. By Distribution Channel
17.5. Market Attractiveness Analysis
17.5.1. By Country
17.5.2. By Type
17.5.3. By Disease Indication
17.5.4. By Distribution Channel
17.6. Market Trends
17.7. Key Market Participants - Intensity Mapping
17.8. Drivers and Restraints - Impact Analysis
18. Middle East and Africa Acquired Orphan Blood Disease Market Analysis 2019-2023 and Forecast 2024-2032
18.1. Introduction
18.2. Pricing Analysis
18.3. Historical Market Size (US$ Bn) and Volume Trend Analysis by Market Taxonomy, 2019-2023
18.4. Market Size (US$ Bn) and Volume Forecast by Market Taxonomy, 2024-2032
18.4.1. By Country
18.4.1.1. GCC Countries
18.4.1.2. Turkey
18.4.1.3. Northern Africa
18.4.1.4. South Africa
18.4.1.5. Rest of Middle East and Africa
18.4.2. By Type
18.4.3. By Disease Indication
18.4.4. By Distribution Channel
18.5. Market Attractiveness Analysis
18.5.1. By Country
18.5.2. By Type
18.5.3. By Disease Indication
18.5.4. By Distribution Channel
18.6. Market Trends
18.7. Key Market Participants - Intensity Mapping
18.8. Drivers and Restraints - Impact Analysis
19. Emerging Countries Acquired Orphan Blood Disease Market Analysis
19.1. Introduction
19.1.1. Market Value Proportion Analysis, By Key Countries
19.1.2. Global Vs. Country Growth Comparison
19.2. U.S. Acquired Orphan Blood Disease Market Analysis
19.2.1. By Type
19.2.2. By Disease Indication
19.2.3. By Distribution Channel
19.3. Canada Acquired Orphan Blood Disease Market Analysis
19.3.1. By Type
19.3.2. By Disease Indication
19.3.3. By Distribution Channel
19.4. Mexico Acquired Orphan Blood Disease Market Analysis
19.4.1. By Type
19.4.2. By Disease Indication
19.4.3. By Distribution Channel
19.5. Brazil Acquired Orphan Blood Disease Market Analysis
19.5.1. By Type
19.5.2. By Disease Indication
19.5.3. By Distribution Channel
19.6. Germany Acquired Orphan Blood Disease Market Analysis
19.6.1. By Type
19.6.2. By Disease Indication
19.6.3. By Distribution Channel
19.7. Italy Acquired Orphan Blood Disease Market Analysis
19.7.1. By Type
19.7.2. By Disease Indication
19.7.3. By Distribution Channel
19.8. France Acquired Orphan Blood Disease Market Analysis
19.8.1. By Type
19.8.2. By Disease Indication
19.8.3. By Distribution Channel
19.9. U.K. Acquired Orphan Blood Disease Market Analysis
19.9.1. By Type
19.9.2. By Disease Indication
19.9.3. By Distribution Channel
19.10. Spain Acquired Orphan Blood Disease Market Analysis
19.10.1. By Type
19.10.2. By Disease Indication
19.10.3. By Distribution Channel
19.11. BENELUX Acquired Orphan Blood Disease Market Analysis
19.11.1. By Type
19.11.2. By Disease Indication
19.11.3. By Distribution Channel
19.12. Russia Acquired Orphan Blood Disease Market Analysis
19.12.1. By Type
19.12.2. By Disease Indication
19.12.3. By Distribution Channel
19.13. China Acquired Orphan Blood Disease Market Analysis
19.13.1. By Type
19.13.2. By Disease Indication
19.13.3. By Distribution Channel
19.14. Japan Acquired Orphan Blood Disease Market Analysis
19.14.1. By Type
19.14.2. By Disease Indication
19.14.3. By Distribution Channel
19.15. S. Korea Acquired Orphan Blood Disease Market Analysis
19.15.1. By Type
19.15.2. By Disease Indication
19.15.3. By Distribution Channel
19.16. India Acquired Orphan Blood Disease Market Analysis
19.16.1. By Type
19.16.2. By Disease Indication
19.16.3. By Distribution Channel
19.17. ASEAN Acquired Orphan Blood Disease Market Analysis
19.17.1. By Type
19.17.2. By Disease Indication
19.17.3. By Distribution Channel
19.18. Australia and New Zealand Acquired Orphan Blood Disease Market Analysis
19.18.1. By Type
19.18.2. By Disease Indication
19.18.3. By Distribution Channel
19.19. GCC Countries Acquired Orphan Blood Disease Market Analysis
19.19.1. By Type
19.19.2. By Disease Indication
19.19.3. By Distribution Channel
19.20. Turkey Acquired Orphan Blood Disease Market Analysis
19.20.1. By Type
19.20.2. By Disease Indication
19.20.3. By Distribution Channel
19.21. Northern Africa Acquired Orphan Blood Disease Market Analysis
19.21.1. By Type
19.21.2. By Disease Indication
19.21.3. By Distribution Channel
19.22. South Africa Acquired Orphan Blood Disease Market Analysis
19.22.1. By Type
19.22.2. By Disease Indication
19.22.3. By Distribution Channel
20. Market Structure Analysis
20.1. Market Analysis by Tier of Companies (Linear Alpha-Olefins)
20.2. Market Share Analysis of Top Players
20.3. Market Presence Analysis
21. Competition Analysis
21.1. Competition Dashboard
21.2. Competition Benchmarking
21.3. Competition Deep Dive
21.3.1. Alexion Pharmaceuticals, Inc.
21.3.1.1. Overview
21.3.1.2. Product Portfolio
21.3.1.3. Profitability by Market Segments (Product/Channel/Region)
21.3.1.4. Sales Footprint
21.3.1.5. Strategy Overview
21.3.2. Amgen, Inc.
21.3.2.1. Overview
21.3.2.2. Product Portfolio
21.3.2.3. Profitability by Market Segments (Product/Channel/Region)
21.3.2.4. Sales Footprint
21.3.2.5. Strategy Overview
21.3.3. Celgene Corporation
21.3.3.1. Overview
21.3.3.2. Product Portfolio
21.3.3.3. Profitability by Market Segments (Product/Channel/Region)
21.3.3.4. Sales Footprint
21.3.3.5. Strategy Overview
21.3.4. Eli Lilly and Company
21.3.4.1. Overview
21.3.4.2. Product Portfolio
21.3.4.3. Profitability by Market Segments (Product/Channel/Region)
21.3.4.4. Sales Footprint
21.3.4.5. Strategy Overview
21.3.5. Sanofi S.A.
21.3.5.1. Overview
21.3.5.2. Product Portfolio
21.3.5.3. Profitability by Market Segments (Product/Channel/Region)
21.3.5.4. Sales Footprint
21.3.5.5. Strategy Overview
21.3.6. GlaxoSmithKline plc.
21.3.6.1. Overview
21.3.6.2. Product Portfolio
21.3.6.3. Profitability by Market Segments (Product/Channel/Region)
21.3.6.4. Sales Footprint
21.3.6.5. Strategy Overview
21.3.7. Cyclacel Pharmaceuticals, Inc.
21.3.7.1. Overview
21.3.7.2. Product Portfolio
21.3.7.3. Profitability by Market Segments (Product/Channel/Region)
21.3.7.4. Sales Footprint
21.3.7.5. Strategy Overview
21.3.8. Onconova Therapeutics, Inc.
21.3.8.1. Overview
21.3.8.2. Product Portfolio
21.3.8.3. Profitability by Market Segments (Product/Channel/Region)
21.3.8.4. Sales Footprint
21.3.8.5. Strategy Overview
21.3.9. Incyte Corporation
21.3.9.1. Overview
21.3.9.2. Product Portfolio
21.3.9.3. Profitability by Market Segments (Product/Channel/Region)
21.3.9.4. Sales Footprint
21.3.9.5. Strategy Overview
21.3.10. CTI BioPharma Corp.
21.3.10.1. Overview
21.3.10.2. Product Portfolio
21.3.10.3. Profitability by Market Segments (Product/Channel/Region)
21.3.10.4. Sales Footprint
21.3.10.5. Strategy Overview
22. Assumptions and Acronyms Used
23. Research Methodology